Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Works in Metabolic & endocrine
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is a clinical trial sponsor. It has 3 active clinical trials with 4,736 planned participants, in Metabolic & endocrine. Since 2021 it has completed 6 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 4,736 planned participants, in Metabolic & endocrine. Since 2021 it has completed 6 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-21.
Approve Suite is not affiliated with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.